E-mail: email@example.com Telephone: +31 53 489 3115 Fax: +31 53 489 3511 Address: Faculty of Science and Technology Medical Cell BioPhysics (MCBP) Building: Carré Room: CR4407
Ruchi Bansal is an Assistant Professor (Tenure-Track) at the University of Twente, The Netherlands. She obtained her Bachelor’s and Master’s degree in Biochemistry from Delhi University, India. In 2012, She obtained her PhD from Pharmacokinetics, Toxicology and Targeting, University of Groningen. Her PhD project was focused on designing of novel strategies to target interferon gamma and its signaling domain to the target pathogenic cells in the chronic diseases (liver fibrosis and Cancer). During the last stages of her PhD, she received two prestigious grants Sheila Sherlock research fellowship (from European association for the study of liver diseases, EASL) and The Ruth and Richard Julin’s Foundation Swedish research grant for postdoctoral research at Karolinska Institute, Stockholm, Sweden. Her research project was focused on “Pathogenesis of Hepatitis C virus (HCV)-induced and alcohol-induced liver diseases”. In October 2012, she started as a senior postdoctoral researcher at the Department of Biomaterials Science and Technology at University of Twente. In 2014, she received a prestigious VENI grant (from NWO, ZonMw) to pursue her research on “Development of novel targeted nano-therapeutics for the treatment of liver diseases”. She has received several awards/honors for her pioneering work and several research grants for pursuing her research. Ruchi has established her independent research team “The Liver Lab” now known as "Translational Liver Research" focused on Liver diseases: from understanding liver disease pathogenesis to nanotherapeutics at the University of Twente, The Netherlands. She is also a Young Academy board member and faculty council member at the University of Twente.
Understanding underlying mechanisms for the development of advanced targeted Nano-theranostics for diagnosis and therapy for liver diseases. Liver diseases are a growing health problem, with a worldwide mortality of around 1.2 million deaths per year attributable to cirrhosis and primary liver cancer. Liver injury caused by chronic viral infections (mainly HBV and HCV), excessive alcohol consumption, metabolic disorders (fatty diet and obesity) leads to liver inflammation, followed by the development of fibrosis (scar tissue formation and loss-of-liver-function) and further progressing to liver carcinoma. Hepatic stellate cells (liver myofibroblasts) are known as producers of fibrosis, and inflammatory macrophages are known as regulators of fibrosis. The cross-talk between these cells plays a crucial role in the progression of liver diseases. The molecular mechanisms leading to aberrant activation of these cells and the regulatory cellular processes involved are incompletely understood, and therefore molecular therapies for the treatment of liver fibrosis are not yet available for clinical use. Therefore, there is an urgent unmet need to understand the underlying mechanisms involved in the disease pathogenesis. On the basis of the understanding, it will therefore be possible to develop new in vitro, in vivo and ex vivo models for the disease modeling, and design new approaches for the diagnosis and treatment of liver diseases. The primary goal of research is to design, develop and evaluate the novel approaches for the diagnosis and treatment of liver diseases and she ambitiously aim to bring these novel therapies to the market for the clinical applications as future personalized medicines.
Hind Rattan (Jewel of India) Award 2019, the highest Indian diaspora honor (highly prestigious) given annually to non-resident persons of Indian origin (NRI’s) (https://en.wikipedia.org/wiki/Hind_Rattan). The award presented at the annual congress on the eve of India’s republic day.
Young Investigator award ($1000), American association for study for liver diseases (AASLD) Liver meeting, November 2018, San Francisco, USA.
Young Investigator award (€750), United European Gastroenterology week, Oct 2018, Vienna, Austria.
National Scholar Award, United European Gastroenterology week, Oct 2017, Barcelona, Spain.
Young Investigator award (€1000), United European Gastroenterology week, Oct 2017, Barcelona, Spain.
Young Investigator award (€1000), United European Gastroenterology week, Oct 2016, Vienna, Austria.
EASL Young Investigator award, EASL The International Liver Congress, 2016, Barcelona, Spain.
Young Investigator award (€1000), United European Gastroenterology week, Oct 2015, Barcelona, Spain.
Junior scholar award for attending Viral Hepatitis Congress (VHC), 2015, Frankfurt, Germany.
Young Investigator award (€1000), United European Gastroenterology week, Oct 2014, Vienna, Austria.
EASL Young Investigator award (€650), EASL The International Liver Congress, 2013, Amsterdam, Netherlands.
AASLD Presidential Poster of Distinction award, American association for Study for Liver Diseases (AASLD) Liver meeting, November 2011, San Francisco, USA.
EASL Young Investigator award (€650), EASL monothematic conference, 2011, Petersburg, Germany.
EASL Young Investigator award (€650), EASL The International Liver Congress, 2011, Berlin, Germany.
Selected for Federation of Innovative Drug Research (FIGON) National PhD competition.
2nd Best Poster Presentation award (€500) at FIGON Dutch Medicine Days, Netherlands.
EASL Young Investigator award (€650), EASL The International Liver Congress, 2010, Vienna, Austria.